diquafosol ophthalmic solution
DrugDE-089 topical ocular application, 6 times daily for 4 weeks.
Other names: HA
NCT Number: NCT01101984
Safety and efficacy of DE-089 ophthalmic solution in patients with dry eye will be evaluated in comparison with sodium hyaluronate ophthalmic solution.
Looking for future studies?
Notify Me21 year–69 year
All sexes
Interventional
Not applicable
Eye & Ear Hospital of Fudan University, Shanghai, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
DE-089 topical ocular application, 6 times daily for 4 weeks.
Other names: HA
0.1% HA topical ocular application, 6 times daily for 4 weeks.
Time frame: 2 weeks and 4 weeks from baseline.
Time frame: 2 weeks and 4 weeks from baseline.
Changes in tear film breakup time (second) 2 weeks, 4 week after the study / at the discontinuation
Looking for future studies?
Notify MeSanten Pharmaceutical Co., Ltd.
Industry
A Randomized, Parallel- Group Comparison Study of DE-089 Ophthalmic Solution in Patients With Dry Eye (Comparison With 0.1% Sodium Hyaluronate Ophthalmic Solution) - A Multinational Study -
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07298811
Dry Eye, Dry Eye Syndromes
Nanchang, Jiangxi, China
View Trial DetailsNCT04413370
Dry Eye, Dry Eye Syndromes
Guangzhou, Guangdong, China
View Trial DetailsNCT07175909
Dry Eye, Dry Eye Disease (DED)
Hong Kong
View Trial DetailsNCT07816419
Arthralgia, Asthenopia
Riyadh, Saudi Arabia
View Trial Details